Neuroendocrine and Mifepristone Level Outcomes
Cortisol and ACTH levels increased with active treatment; the change in levels from baseline to 1 week differed significantly between the groups (In the mifepristone group only, responders (n = 15) vs nonresponders (n = 23) did not differ significantly in posttreatment median cortisol (13.2 vs 13.3 μg/dL [to convert to nanomoles per liter, multiply by 27.588]) or ACTH (median, 29.7 vs 22.1 pg/nL [to convert to picomoles per liter, multiply by 0.22]) levels. Within the entire sample, respondents had higher, but not significantly different, posttreatment ACTH and cortisol levels than nonresponders. When extreme ACTH outliers (1 in each group) were removed (eFigure 2 in Compared with nonresponders, mifepristone responders showed lower median levels of mifepristone (1305 vs 1610 ng/mL, 